Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic medication. It is traditionally used against worms, but more recently found to be effective against mites and some lice too. Ivermectin is currently being used to help eliminate river blindness (onchocerciasis) in the Americas and stop transmission of lymphatic filariasis around the world.
Acceptance of COVID-19 vaccines increased globally, from 75.2% in 2021 to 79.1% in 2022, according to a survey in 23 countries that represent more than 60% of the world's population.
Researchers assessed the impact of ivermectin on the duration of sustained recovery among coronavirus disease 2019 (COVID-19) outpatients.
Uptake of national guidelines for the treatment of children hospitalized with COVID-19 fell well below what would typically be expected, report researchers at the Medical University of South Carolina (MUSC) and elsewhere in Pediatrics.
Researchers assessed the impact of drug combinations on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suppression.
A new study evaluated the effect of ivermectin on time to recovery from coronavirus disease 2019 (COVID-19) in patients with mild to moderate disease.
In silico studies assess the binding efficacy of phytoconstituents against active sites of SARS-CoV-2.
The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.
The ongoing war in Ukraine has caused massive destruction in the region, enhancing the risk of epidemic typhus.
Researchers conducted a phase III clinical trial to test the effectiveness of three repurposed drugs - metformin, ivermectin, and fluvoxamine, in preventing progression to severe COVID-19.
A recent study reviewed the existing treatment modalities, including vaccines and antivirals, for SARS-CoV-2 infection.
In a recent study posted to the medRxiv* pre-print server, researchers in Israel described the case of a severely immunocompromised cancer patient who developed a chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
There remains no evidence to support the use of ivermectin for treating or preventing COVID-19 infection, state the authors of an updated Cochrane Review, which now contains 11 trials across 3409 people.
Health inequalities facing women and girls, already stark before the onset of COVID-19, have widened glaringly during the pandemic. Lockdowns restricted access to sexual and reproductive health services, increased violence against women, and interrupted girls’ education.
Researchers showed that Google search data could be utilized for monitoring the spread of COVID-19 cases.
Not long ago, Kansas showed strong bipartisan support for vaccines as a tool to support a robust public health system.
In March 2020, Dr. Joseph Vinetz left the contemplative world of his Yale University infectious-disease laboratory and plunged into the covid ward at Yale New Haven Hospital, joining an army of health care workers who struggled to treat the deadly viral disease.
Researchers identified drugs inhibiting the entry of SARS-CoV-2.
A recent study published in the New England Journal of Medicine investigated the impact of ivermectin, an antiparasitic drug, as an early treatment option among coronavirus disease 2019 (COVID-19) patients.
Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.
While the vast majority of U.S. adults who are fully vaccinated and boosted against Covid-19 would be likely to recommend vaccinating a 5- to 11-year-old, over a third of fully vaccinated adults who have not had a booster shot have reservations about Covid-19 vaccination for a child that age, according to survey data analysis by the Annenberg Public Policy Center of the University of Pennsylvania.